<DOC>
	<DOCNO>NCT02073279</DOCNO>
	<brief_summary>The objective study evaluate efficacy , safety , pharmacodynamic , pharmacokinetic immunogenic profile SA237 patient NMO NMOSD</brief_summary>
	<brief_title>Efficacy Safety Study Monotherapy SA237 Treat NMO NMOSD</brief_title>
	<detailed_description />
	<mesh_term>Neuromyelitis Optica</mesh_term>
	<criteria>1 . NMO NMOSD 2 . Age 18 74 year , inclusive time inform consent . 1 . Pregnancy lactation . 2 . Evidence demyelinate disease PML . 3 . Known active infection ( exclude fungal infection nail bed caries dentium ) within 4 week prior baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>